![Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population | Prostate Cancer and Prostatic Diseases Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fpcan.2016.57/MediaObjects/41391_2017_Article_BFpcan201657_Fig1_HTML.jpg)
Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population | Prostate Cancer and Prostatic Diseases
![CAPRA-S scores and projection of prostate cancer recurrence post-surgery | THE "NEW" PROSTATE CANCER INFOLINK CAPRA-S scores and projection of prostate cancer recurrence post-surgery | THE "NEW" PROSTATE CANCER INFOLINK](https://talkaboutprostatecancer.files.wordpress.com/2011/06/capra-s-rev.png)
CAPRA-S scores and projection of prostate cancer recurrence post-surgery | THE "NEW" PROSTATE CANCER INFOLINK
![Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.](https://d3i71xaburhd42.cloudfront.net/cfb41af6cecfb5f204e79875232cee8734801010/3-Table3-1.png)
Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
![Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator - European Urology Focus Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/attachment/adf2d3f5-f120-4033-88a6-3fc175a7a0aa/gr1.jpg)
Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator - European Urology Focus
![A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc](https://www.urotoday.com/images/stories/Beyond_the_Abstract/bta_zhu_fig1c.jpg)
A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc
![Article of the Week: ERSPC risk calculators significantly outperform the PCPT 2.0 in the prediction of PCa - BJUI Article of the Week: ERSPC risk calculators significantly outperform the PCPT 2.0 in the prediction of PCa - BJUI](https://www.bjuinternational.com/wp-content/uploads/2016/11/AOTWNov-2-FI.jpg)
Article of the Week: ERSPC risk calculators significantly outperform the PCPT 2.0 in the prediction of PCa - BJUI
![Prostate Cancer Risk Calculator' mobile applications (Apps): a systematic review and scoring using the validated user version of the Mobile Application Rating Scale (uMARS) | SpringerLink Prostate Cancer Risk Calculator' mobile applications (Apps): a systematic review and scoring using the validated user version of the Mobile Application Rating Scale (uMARS) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00345-017-2150-1/MediaObjects/345_2017_2150_Fig2_HTML.gif)
Prostate Cancer Risk Calculator' mobile applications (Apps): a systematic review and scoring using the validated user version of the Mobile Application Rating Scale (uMARS) | SpringerLink
![PROSTATE CANCER RISK CALCULATOR COMPARISON: IPCRC vs KPCRC vs PCPT-RC vs ERSPC-RC IN PREDICTING PROSTATE CANCER AT HASAN SADIKIN HOSPITAL | Indonesian Journal of Urology PROSTATE CANCER RISK CALCULATOR COMPARISON: IPCRC vs KPCRC vs PCPT-RC vs ERSPC-RC IN PREDICTING PROSTATE CANCER AT HASAN SADIKIN HOSPITAL | Indonesian Journal of Urology](http://juri.urologi.or.id/public/journals/1/cover_issue_38_en_US.jpg)
PROSTATE CANCER RISK CALCULATOR COMPARISON: IPCRC vs KPCRC vs PCPT-RC vs ERSPC-RC IN PREDICTING PROSTATE CANCER AT HASAN SADIKIN HOSPITAL | Indonesian Journal of Urology
Mobile Application-Based Seoul National University Prostate Cancer Risk Calculator: Development, Validation, and Comparative Analysis with Two Western Risk Calculators in Korean Men | PLOS ONE
Indonesian Prostate Cancer Risk Calculator (IPCRC): An application for Predicting Prostate Cancer Risk (a Multicenter Study)
![Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK Developing a national, Web-based, patient-focused, prostate cancer data monitoring system | THE "NEW" PROSTATE CANCER INFOLINK](https://talkaboutprostatecancer.files.wordpress.com/2009/12/mskcc-image-d.jpg?w=584)